TAKE Solutions Ltd. Enabling Business Efficiencies Corporate - - PowerPoint PPT Presentation

Corporate Presentation

October, 2011

TAKE Solutions Ltd.

Enabling Business Efficiencies

TAKE: Technology, Analytics & Knowledge for the Enterprise

2

Contents

 TAKE – At A Glance  Business Model & Market Potential  Competencies

− Life Sciences − Supply Chain Management

 Financials  Growth Strategies & Key TAKEaways  Appendix

3

TAKE Solutions – At A Glance

 Headquartered in Chennai, India, TAKE Solutions Ltd.

delivers technology, services and expert advice in Life Sciences and Supply Chain Management domains

 Strong presence in US, Europe and Middle East Asia: US

contributes approx. 2/3 of revenue

 Serves over 150 of the top 1,000 Fortune companies  CMMi Level 5 and PCMM Level 3 accredited company  Corporate

Sponsor

• f

Clinical Data Interchange Standards Consortium (CDISC) and ACI has a Registered Solution Provider (RSP) status

 Recognitions:

• TAKE is ranked Leader in the life science R&D IT
• utsourcing market by IDC, a premier global provider
• f market intelligence and advisory services IT

markets

• Ranked first by a premier global analyst firm, for

industry expertise and overall customer satisfaction in Life Sciences domain

• 2011 Supply and Demand Chain Executive 100 List
• “Editors’ Pick” Distinction by Consumer Goods

Technology Magazine

 We serve 400+ clients through 14 offices globally

with 1,100+ employees

 Life Sciences: Celgene, Eisai, Johnson & Johnson,

Merck, Neuromed, Novartis, Pfizer, Roche, Sanofi Aventis

 SCM: Applied Materials, Alcoa, GE Group,

Honeywell, Panasonic, ITC, Pepsi, Transocean, Xerox

About TAKE Marquee Clients Financials

 Over the last five years, revenue has grown at CAGR

• f 61% while net profit has grown at CAGR of 69%

30 60 90 120 FY05 FY06 FY07 FY08 FY09 FY10 FY11 USD mn Revenue Net profit

4

Global Footprint

Chennai, India Austin & El Paso, TX Philadelphia, PA Muscat, Oman Princeton, NJ

TAKE Solutions Inc. 502 Carnegie Center, Suite 100, Princeton, NJ

USA HQ

TAKE Solutions Ltd. No.8B, Adyar Club Gate Road, Chennai - 600028, India

Global HQ

Riyadh, Jeddah & Al-Khobar Saudi Arabia Dubai, UAE

Strong Presence in the US, Middle East Asia and Europe

Hampshire, UK

TAKE Solutions LLP Shriram "The Gateway SEZ", Perungalathur, Chennai, India

Global Delivery Center

Singapore Kuwait

5

Recognitions and Partnerships



CMMi Level 5 and PCMM level 3



2011: IDC, a global market intelligence firm, ranked TAKE as Leader in the life science R&D IT outsourcing market based

• n the company’s capabilities and future strategies aligned

with what customers will require in three to five years



2011 Supply & Demand Chain Executive 100 list



2010: A premier global analyst firm recognized and ranked TAKE, first among large system integrators for industry expertise & overall customer satisfaction in the Life Sciences Domain



2010 Great Supply Chain Partner by SupplyChainBrain



2010 “Editors’ Pick” Distinction by Consumer Goods Technology Magazine



Global Logistics & Supply Chain Strategies 2010: 100 Great Supply Chain Partners List



2010: Listed in Food Logistics 100 for Fourth Consecutive Year



Manufacturing Business Technology Emerging 40 Vendor List (USA)



Madras Management Association (MMA) Award 2010 for Managerial Excellence in the Services Category  Oracle Gold Partner  SAP Business Objects Gold Partner  Microsoft BIO IT alliance Partner  CDISC Solutions Partner  Microsoft’s Digital Pharma Initiative  Microsoft High Impact Gold partner  Others: Cegedim Relationship Management,

Cross Gate, QlikTech, DataMAX, Firefox & Intermec

Certifications & Accreditation Alliances and Partnerships

Business Model & Market Potential

7

TAKE Solutions – Business Model

DOMAIN

Supply Chain Management & Life Sciences

TECHNOLOGY

Service Oriented Architecture (SOA) Cloud Computing Virtualization

DELIVERY model REVENUE model

SaaS On Premise Business Services



Embedded / RFID / Mobile Licenses Maintenance

TRANSACTIONS / SUBSCRIPTIONS

Services

    

8

TAKE Solutions – Business Model

 Balanced: Well distributed across two key verticals - niche offerings addressing multiple

end user industries

 Wide Portfolio of Offerings: Solutions to address customer needs - Solutions delivered

as business services, products and SaaS

 Diversified Customer Base: Portfolio of solutions to address customer size - focused

approach to large & mid-market customer segment and wider approach to SME segment

 Scalable: Platform agnostic solutions to enhance addressable markets and strategic

partnerships to drive penetration in areas of specialization

 Diversified Revenue Streams: Income from subscription, licensing, royalties, services and

AMC leading to a mix of annuity and non annuity revenues

9

Total Addressable Market

1.0 8.0 40.0 0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 SaaS On Premise Business Services USD billion 5.7 10.2 0.0 2.0 4.0 6.0 8.0 10.0 12.0 Pre - Approval Post- Approval USD billion

Supply Chain Management Life Sciences

Domain Competency Life Sciences

11

Integrated Solutions & Services

Discovery Development Commercialization Research Preclinical Phase I Phase II Phase III Phase IV Technology Solutions √ √ √ √ CTMS EDC CDMS eDMS eSub CDR/LSH PV Development Process Services Individual offerings SAS Programming Biostatistics Clinical Data Standardization Document & Submission Publishing Milestone based & Multi-milestone Solutions IND/CTA to NDA Legacy Data Standardization Document & Submission publishing Data Integration & Clinical Data Repository

Kindly refer the Appendix at the end of the presentation for the meanings of the acronyms used above

Software products - Life Sciences

CDISC Accelerators PharmaReady DMS PharmaReady eCTD PharmaReady SPL/PLR PharmaReady TRMS SafetyView PharmaReady PPM

SAS - Bio Statistics Framework

Clinical Development Bio Statistical Programming Regulatory Submissions Safety

pvNet pvConnect PharmaReady eTMF

CLINICAL REGULATORY SAFETY Oracle Life Sciences

Oracle Clinical Phase Forward Siebel CTMS IMPACT Argus Safety AERS LSH

12

13

Business Services – Life Sciences

Clinical Data Warehouses ePublishing NDA/IND/ANDA Document Publishing Document Archival Safety Analytics Safety Signal Detection Core Data Sheets Literature Scanning Case Processing DMCs Data Standardization NDA preparation Biostatistics Programming Data Management

Regulatory Clinical Safety

Medical Writing & Coding Trial Master File

Customer A Therapeutic Area 1 Indication A Indication B Phase1 Study I Phase2 Study 1 Therapeutic Area 2 Indication C Customer B Therapeutic Area 1 Indication D Indication E Phase1 Study 1 Study 1 Study 1 Phase2 Study 1 Study 1 Study 1 Therapeutic Area 2 Customer C Therapeutic Area 1 Customer D Therapeutic Area 1

Established customer relationships; scalable revenue model

14

Technology + business services

TLFs, Biostatistics, SDTM, ADaM, ISS/ISE, DMCs, SAP, EAC, NDAs Increasing customer base Multiplying revenues

15

TAKE Life Sciences - Differentiators

 Unique combination of deep domain expertise and technical skills  Market penetration across

• Bio-pharmaceutical (branded & generic)
• Medical device
• CROs

 Mature infrastructure across USA and APAC

• People
• Process
• Infrastructure – SAS 70* compliant, validated data center

 Strategic partnerships with Oracle and Liquent  TAKE’s differentiated approach to markets

• Large and mid-market segment : Functional Service Provider
• Small and medium segment

: Full Service Provider

* SAS 70 (the Statement on Auditing Standards No. 70) defines the standards an auditor must employ in order to assess the contracted internal controls of a service organization. Service organizations, such as hosted data centers, insurance claims processors and credit processing companies, provide outsourcing services that affect the operation of the contracting enterprise.

16

TAKE Life Sciences - Strategy

• Continuously enhancing solutions portfolio to address additional areas of clinical,

regulatory and safety leading to larger ticket size of contracts

• Reducing dependency on the US market
• WCI acquisition to give European footprint
• Expansion in other developed geographic like Europe and developing regions like Asia Pacific
• Deepening engagement at existing campuses to enable participation in greater

proportion of overall R&D spend

• Proactively positioning services and offerings in geographies which are mandating

regulatory filing in electronic mode

• Leveraging partnerships and alliances with Oracle, Liquent & Cegedim Relationship

Management to increase product user base as well as expand addressable customer base

17

TAKE assessed as a LEADER in Life Sciences

“TAKE has built a strong list of clients, based on its deep domain knowledge, willingness to engage customers as partners, IP-based solutions, and thought leadership in clinical, regulatory, drug safety, and other life science areas.” “TAKE's diverse customer base, broad services portfolio, strong commitment to life science industry-specific growth, domain-centric expertise, and strong customer relationships make TAKE is a fierce competitor in winning projects that the company competes for.”

Source: IDC MarketScape: Worldwide Life Science R&D IT Outsourcing 2011 Vendor Assessment, August 2011

Excerpt from the Report:

• Capabilities: Evaluated on current capabilities and how well aligned it is to customer needs
• Strategies: Indicates how well the company’s future strategy aligns with what customers will require in

three to five years

Understanding customer profiles –Market Potential

Pharmaceutic al Biotechnology Consumer Health Animal Health Crop Science/Agroc hemicals Medical Devices Dietary Supplements Cosmetics Tobacco Generics Turnover > $100m 744 172 63 53 116 128 72 60 46 44 Turnover > $250m 476 123 53 44 100 99 56 52 40 40 Turnover > $500m 351 98 41 38 84 81 43 45 35 32 Turnover > $1b 257 88 34 27 71 60 36 35 29 22 257 88 34 27 71 60 36 35 29 22 351 98 41 38 84 81 43 45 35 32 476 123 53 44 100 99 56 52 40 40 744 172 63 53 116 128 72 60 46 44 200 400 600 800 1000 1200 1400 1600 1800 2000 Number of companies Customer/prospect type

Number of customers/prospects by type

18

Geographical spread of customers/prospects

North America Europe Africa Asia Australasia South America Generics 49 17 2 13 1 Tobacco 48 13 9 2 Cosmetics 175 1270 3 661 5 Dietary Supplements 150 23 2 34 1 1 Medical Devices 285 79 16 1 Crop Science/Agrochemicals 166 47 2 104 6 30 Animal Health 120 335 95 3 Consumer Health 83 27 2 20 1 Biotechnology 587 162 34 8 Pharmaceutical 4018 3757 33 3139 107 185 1000 2000 3000 4000 5000 6000 7000 Number of customers/prospects Geography

Customers/prospects by geography

19

20

Diverse Customer Base : Life Sciences

Bio-Tech CROs / Academic Pharma Generics / OTC Devices

We serve 7 of top 10 global pharmaceutical companies

Domain Competency Supply Chain Management

Software Products

 SNG, XPC, Resonance  ERM  TAKE IPOINT, Take Forward, Take Hub  Insight, Cameo, Optima

Value Chain Collaboration

 Gemini (Process Manufacturing)  Gemini (Discrete Manufacturing)  Compliance Label Manager  RoutePro

Enterprise Mobility & Auto-ID

 NAFTAssistant  CAM  e-Request

Global Trade Management

On Premise Products SaaS Platform

 New generation fulfillment on multi-

tenancy model

Products in Pipeline

 Gemini for SAP

Products in Pipeline Products in Pipeline

 GTM on SaaS Platform  OneSCM

TAKE Business Cloud

 Social enterprise- perception tracking,

Customer insight & service

Products in Pipeline

22

23

Business Services

Spend Analytics Supplier Performance Supplier Selection Contract Administration Consulting & Insight NAFTA Compliance AP automation Catalog Services Supplier Enablement Invoice Processing Requisition Processing Reverse Engineering Value Engineering Prototyping Simulation & Testing Design Drawing & Documentation

Sourcing Support Sourcing

• Engg. Services

Procurement Operations

24

Business Strategy

 Augmenting product & service offerings to enhance overall customer

experience and business transformation

 Investing in new engagement models to drive the demand such as Software as

a Service (SaaS)

 Increase penetration in high potential geographies (e.g. Europe, Emerging

Markets) in addition to consolidation of presence in existing markets (US, Middle East, Asia)

 Forging alliances with leading ERP vendors to drive visibility, expand reach &

increase volumes



Revenue – Pent-up demand and revival of investment in ERP is driving software sales

• Scalability and functionality advantage in GTM, Auto-ID & Supply Management
• Repeat business and longer term engagement

– Outcome oriented end-to-end process outsourcing driving consulting and business services revenue

• 100 existing customers in the $1 - 6 Billion (turnover) range provide a captive base for

business services – Subscription and software as a service driving Supply Chain on the cloud

• User adoption crossing 25,000 for OneSCM
• New monetization opportunities by leveraging the community



Geographic Reach – Leverage success of US model in Europe – Build on the leadership position in the Middle East

Growth Drivers…

25

26

Diverse Customer Base - Global SCM Customers

Pharma & Medical Industrial Products/ Services Consumer Products High Tech FMCG / Food Oil & Gas

Financial Highlights

28

Financial Overview

Strong growth and momentum across the operating segments

Revenue (Rs Mn) EBITDA (Rs Mn) EPS (Rs) PAT (Rs Mn)

* Pre - IPO EPS

1,828 2,967 3,403 3,664 5,061 FY07 FY08 FY09 FY10 FY11 467 793 782 714 1,091 FY07 FY08 FY09 FY10 FY11 316 529 529 324 700 FY07 FY08 FY09 FY10 FY11 3.5 4.74 4.44 2.7 5.82 FY07 FY08 FY09 FY10 FY11

*

29

Revenue Analysis

Revenue By Category Revenue By Geography Revenue By Vertical

73% 63% 65% 27% 37% 33% 2% FY09 FY10 FY11 US AsiaPac Europe 48% 53% 49% 45% 41% 47% 7% 6% 4% FY09 FY10 FY11 SCM LS Others

49% 56% 59% 32% 24% 22% 16% 13% 11% 3% 7% 8% FY09 FY10 FY11

Services Prod Lic & Related Activities AMC Others

30

Group Order Book

18.5 21.5 22.1 23.0 26.6 28.4 28.3 30.3 31.1 22.5 23.8 25.2 26.0 25.2 28.8 33.4 40.5 41.4

0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 Q1 FY10 Q2 FY10 Q3 FY10 Q4 FY10 Q1 FY11 Q2 FY11 Q3 FY11 Q4 FY11 Q1 FY12

USD million SCM LS

41.0 49.0 51.8 57.2 61.7 70.8 45.3 47.3 72.5

31

Share Holding Pattern

Category No of Shares % of Total

Promoter & Promoter Group 71,392,096 58.3% Public Shareholding

• Institutions

Mutual Funds/Financial Institutions/ Banks 6,788,790 5.5% FIIs 2,220,276 1.8% Trust 2,765,422 2.3%

• Non Institutions

Bodies Corporate 16,747,071 13.7% Retail 22,033,174 18.0% Others 453,171 0.4% TOTAL 122,400,000 100.0%

Shareholding Patterns (Jun 30, 2011)

Promoter & Promoter Group, 58.3% Retail, 18.0% Bodies Corporate, 13.7% Mutual Funds/Financial Institutions/ Banks, 5.5% Trust, 2.3% FIIs, 1.8% Others, 0.4%

Growth Strategies And Key TAKEaways

33

Key Growth Strategies

• Remain strongly IP centric :
• Plans

to launch 6 products across LS and SCM over the next two years

• Build

customer focused solutions

• Augment product offerings

with services

• Actively pursue emerging

technologies & standards and incorporate them in

• ur products
• SaaS

Right Product and Service Mix

• Entry

into new geographies

• Increase

revenue contribution from Europe to 20% over the next two years

• Gain

momentum and leadership position in US and Asia Pacific

Exploring New Markets

• Build

Partnerships to make

• ur

products platform agnostic

• DataMAX, Cross

Gate, Cegedim Dendrite, Firefox, Intermec, Liquent, Oracle & SAP

• Inorganic Growth for:
• Products
• Markets
• Customers

Right Investments

Growth Enablers

34

Key TAKEaways

 Strong fundamentals

• Domain expertise
• Marquee client list
• Niche player operating in niche segments
• Strong Portfolio of products and services

 Growth momentum

• Traction in Life Sciences vertical
• Revival in the SCM vertical
• Sustained growth in order book providing visibility

 Improving financials

• Traction in revenue and expansion in margins
• Improvement in key operating metrics and profitability ratios

35

Appendix

Acronyms Meanings

CTMS Clinical Trial Management System EDC Electronic Data Capture CDMS Clinical Data Management System eDMS Electronic Document Management System eSub Electronic Submissions CDR Clinical Data Repository LSH Life Sciences Hub PV Pharmacovigilance IND Investigational New Drug CTA Clinical Trial Authorization NDA New Drug Application PaaS Platform as a Service ETL Extract Transform and Load PO collaboration Purchase Order Collaboration AP automation Accounts Payables Automation

THANK YOU

Disclaimer:

This presentation has been prepared by TAKE Solutions Ltd. (the “Company”) solely for your information and for your use and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person (whether within or outside your organization or firm) or published in whole or in part, for any purpose. By attending this presentation, you are agreeing to be bound by the foregoing restrictions and to maintain absolute confidentiality regarding the information disclosed in these materials. Certain statements in this presentation concerning our future growth prospects are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, intense competition in IT including factors which may affect our cost advantage, wage increases, our ability to attract and retain highly skilled professionals, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in Supply Chain Management (SCM) & Life Sciences (LS), disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our contracts, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property and general economic conditions affecting our industry. TAKE does not undertake to update any forward- looking statement that may be made from time to time by or on behalf of the company.

TAKE: Technology, Analytics & Knowledge for the Enterprise

For further information, please contact: Sachin Garg, sachingarg@takesolutions.com